Nara
← Intervention Library

Experimental and investigational

Epitalon

A synthetic peptide promoted for telomere effects on very thin evidence.

Nara’s current positionEvidence briefing
Evidence briefing

Strongest directness: Other animal evidence. Last reviewed 2026-08-12.

Nara’s evidence view

Not currently supported

Insufficient or conflictingNon-canine preclinical evidenceVery low confidence

The claim we’re evaluating

Epitalon, the synthetic tetrapeptide Ala-Glu-Asp-Gly, extends lifespan or meaningfully improves healthspan in dogs through telomere or other aging-related effects.

Nara’s interpretation

Epitalon has intriguing experimental findings, but the evidence does not establish lifespan or healthspan benefit in dogs. Its frequently cited mouse longevity result did not increase mean lifespan, and the telomere evidence most often used to support the longevity narrative comes from cultured human cells rather than clinical outcomes. Nara should not translate these findings into a canine anti-aging claim.

This is an umbrella assessment. The evidence differs materially depending on the outcome and the specific form of the intervention, so Nara evaluates those narrower claims separately.

Personalized

What this means for your dog.

Loading your dog’s context…

Evidence briefing

What Nara knows now.

A bounded position while the full claim-level dossier is still being completed.

What is known

No peer-reviewed canine intervention study of Epitalon was identified in the targeted search. In a long-term study of female Swiss-derived SHR mice, Epitalon did not alter mean lifespan, although the last 10% of survivors lived longer and maximum lifespan was reported to increase; total spontaneous tumor incidence was unchanged. A separate in-vitro study found induction of telomerase activity and telomere elongation in telomerase-negative human fetal fibroblasts, which establishes a cellular effect rather than organismal longevity. FDA's 2026 evaluation explicitly distinguishes synthetic tetrapeptide Epitalon from epithalamin, a pineal polypeptide complex, meaning older epithalamin human observations cannot automatically be counted as Epitalon evidence.

What is not known

No direct canine efficacy, healthspan, lifespan, pharmacokinetic, or adequate safety evidence was identified. The principal lifespan experiment was a single-strain, female-only mouse experiment using a fixed regimen. Mean lifespan was unchanged in that experiment despite positive maximum-survival endpoints. Maximum lifespan and survival of the longest-lived subset should not be treated as equivalent to a replicated shift in population survival. Telomerase activation and telomere elongation in cultured fetal fibroblasts do not demonstrate improved health, reduced disease, healthspan extension, or lifespan extension in an organism. Epitalon and epithalamin are different substances, making attribution of older pineal-extract studies to synthetic Epitalon scientifically invalid. Independent modern replication of the central longevity claim across laboratories, strains, sexes, and robust survival endpoints was not identified.

Current position

Epitalon has intriguing experimental findings, but the evidence does not establish lifespan or healthspan benefit in dogs. Its frequently cited mouse longevity result did not increase mean lifespan, and the telomere evidence most often used to support the longevity narrative comes from cultured human cells rather than clinical outcomes. Nara should not translate these findings into a canine anti-aging claim.

No peer-reviewed canine intervention study of Epitalon was identified in the targeted search. In a long-term study of female Swiss-derived SHR mice, Epitalon did not alter mean lifespan, although the last 10% of survivors lived longer and maximum lifespan was reported to increase; total spontaneous tumor incidence was unchanged. A separate in-vitro study found induction of telomerase activity and telomere elongation in telomerase-negative human fetal fibroblasts, which establishes a cellular effect rather than organismal longevity. FDA's 2026 evaluation explicitly distinguishes synthetic tetrapeptide Epitalon from epithalamin, a pineal polypeptide complex, meaning older epithalamin human observations cannot automatically be counted as Epitalon evidence.